secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001867096-26-000027
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Biopharma Q1 revenue up 43% to $82M; Recorlev nearly doubles to $50M; raises FY guidance to $380-390M
--------------------------------------------------------------------------------

- Product revenue $82.5M, up 43% YoY; total revenue $83.1M, up 38%. Net income $2.2M vs net loss $9.2M.
- Recorlev net revenue $49.8M, up 95% driven by patient demand; Gvoke flat at $20.8M; Keveyis $11.9M, up 4%.
- Adjusted EBITDA $15.1M, improvement of $10.7M YoY; gross margin improved to 87% from 85%.
- Raises FY2026 total revenue guidance; tightens range to $380-390M (>30% growth at midpoint).
- Plans Phase 3 initiation of XP-8121 later in 2026; commercial team expansion completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000027/0001867096-26-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000027/xers-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001867096-26-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer